ZCM
VIR icon

Zebra Capital Management’s Vir Biotechnology VIR Stock Holding History

Zebra Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$631K Sell
27,110
-10,339
-28% -$264K 3.15% 4
2022
Q4 		$948K Sell
37,449
-2,655
-7% -$65.1K 3.32% 4
2022
Q3 		$773K Buy
40,104
+14,685
+58% +$373K 2.94% 3
2022
Q2 		$647K Buy
25,419
+3,192
+14% +$74.5K 1.9% 14
2022
Q1 		$572K Buy
+22,227
New +$659K 1.31% 25

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Zebra Capital Management's VIR Position: Q1 2023 in Review

Zebra Capital Management reduced its Vir Biotechnology (VIR) stake by 28% in Q1 2023, selling an estimated $264K and leaving 27,110 shares worth $631K. The position accounts for 3.15% of the portfolio, ranked #4.

Zebra Capital Management first reported a position in VIR in Q1 2022 and has held it in 5 quarters since. The position peaked at $948K in Q4 2022. 231 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

  • Zebra Capital Management held 27,110 shares of Vir Biotechnology worth $631K as of Q1 2023.
  • Zebra Capital Management sold 10,339 Vir Biotechnology shares in Q1 2023, an estimated $264K.
  • Vir Biotechnology made up 3.15% of Zebra Capital Management's portfolio in Q1 2023, its #4 holding.
  • Zebra Capital Management first reported a position in Vir Biotechnology in Q1 2022 and has held it in 5 quarters since.
  • Zebra Capital Management's Vir Biotechnology position peaked at $948K in Q4 2022.
  • 231 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on Zebra Capital Management's 13F filing for Q1 2023, filed 15 May 2023.